Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CLPTNASDAQ:DCTHNYSE:INFUNASDAQ:NPCE On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLPTClearPoint Neuro$14.31+7.6%$12.83$5.11▼$19.22$400.25M1.03227,758 shs349,573 shsDCTHDelcath Systems$14.35+23.6%$12.29$5.30▼$16.97$479.76M0.72364,914 shs1.32 million shsINFUInfuSystem$5.47+15.2%$5.31$4.61▼$9.97$114.96M1.7388,748 shs241,648 shsNPCENeuroPace$12.55+3.5%$11.51$5.45▼$15.11$411.05M2.04132,846 shs155,293 shsInvesting Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLPTClearPoint Neuro+1.14%-7.64%+21.37%-29.68%+125.64%DCTHDelcath Systems-0.94%-3.57%+6.42%-29.42%+103.33%INFUInfuSystem+1.06%+0.64%-5.00%-40.99%-36.75%NPCENeuroPace+3.21%+3.21%-1.91%-11.68%-9.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLPTClearPoint Neuro2.4718 of 5 stars3.53.00.00.04.00.00.6DCTHDelcath Systems2.5805 of 5 stars3.53.00.00.01.92.50.6INFUInfuSystem1.6694 of 5 stars2.00.00.00.02.02.51.9NPCENeuroPace2.9153 of 5 stars2.45.00.00.02.74.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLPTClearPoint Neuro 3.00Buy$25.0074.76% UpsideDCTHDelcath Systems 3.00Buy$22.7558.54% UpsideINFUInfuSystem 4.00Strong Buy$13.00137.66% UpsideNPCENeuroPace 2.80Moderate Buy$15.2021.12% UpsideCurrent Analyst Ratings BreakdownLatest INFU, DCTH, CLPT, and NPCE Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/1/2025CLPTClearPoint NeuroStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$19.00 ➝ $25.003/18/2025INFUInfuSystemSidotiSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy3/7/2025DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $24.003/5/2025NPCENeuroPaceCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$19.00 ➝ $20.00(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLPTClearPoint Neuro$31.39M12.75N/AN/A$0.86 per share16.63DCTHDelcath Systems$37.21M12.90N/AN/A$0.72 per share19.93INFUInfuSystem$134.86M0.85$0.43 per share12.79$2.47 per share2.21NPCENeuroPace$79.91M5.14N/AN/A$0.79 per share15.89Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLPTClearPoint Neuro-$22.09M-$0.70N/AN/AN/A-59.64%-62.10%-38.39%5/13/2025 (Estimated)DCTHDelcath Systems-$47.68M-$0.98N/AN/AN/A-150.70%-338.16%-104.02%5/8/2025 (Estimated)INFUInfuSystem$870K$0.1091.1817.65N/A1.12%2.78%1.41%N/ANPCENeuroPace-$32.96M-$0.95N/AN/AN/A-36.74%-205.41%-28.29%5/14/2025 (Estimated)Latest INFU, DCTH, CLPT, and NPCE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025NPCENeuroPace-$0.26N/AN/AN/A$21.85 millionN/A5/13/2025Q1 2025CLPTClearPoint Neuro-$0.15N/AN/AN/A$8.21 millionN/A5/8/2025Q1 2025DCTHDelcath Systems$0.10$0.03-$0.07$0.03$16.83 millionN/A3/6/2025Q4 2024DCTHDelcath Systems-$0.10-$0.11-$0.01-$0.11$14.96 million$15.10 million3/4/2025Q4 2024NPCENeuroPace-$0.25-$0.18+$0.07-$0.18$21.14 million$21.47 million2/26/2025Q4 2024CLPTClearPoint Neuro-$0.15-$0.20-$0.05-$0.20$8.23 million$7.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLPTClearPoint NeuroN/AN/AN/AN/AN/ADCTHDelcath SystemsN/AN/AN/AN/AN/AINFUInfuSystemN/AN/AN/AN/AN/ANPCENeuroPaceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLPTClearPoint NeuroN/A4.543.61DCTHDelcath SystemsN/A1.341.03INFUInfuSystem0.501.981.59NPCENeuroPace6.035.594.77Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLPTClearPoint Neuro30.08%DCTHDelcath Systems61.12%INFUInfuSystem71.13%NPCENeuroPace78.83%Insider OwnershipCompanyInsider OwnershipCLPTClearPoint Neuro6.11%DCTHDelcath Systems17.40%INFUInfuSystem11.40%NPCENeuroPace22.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCLPTClearPoint Neuro11027.98 million25.90 millionOptionableDCTHDelcath Systems6033.43 million26.24 millionOptionableINFUInfuSystem41021.02 million19.10 millionOptionableNPCENeuroPace17032.75 million23.22 millionOptionableINFU, DCTH, CLPT, and NPCE HeadlinesRecent News About These CompaniesNeuroPace, Inc. (NASDAQ:NPCE) Shares Acquired by JPMorgan Chase & Co.May 2, 2025 | marketbeat.comNeuroPace, Inc. (NASDAQ:NPCE) Holdings Decreased by Nantahala Capital Management LLCApril 30, 2025 | marketbeat.comWalleye Capital LLC Acquires New Stake in NeuroPace, Inc. (NASDAQ:NPCE)April 27, 2025 | marketbeat.comNeuroPace Stock Short Interest Report | NASDAQ:NPCE | BenzingaApril 20, 2025 | benzinga.comNeuroPace, Inc. (NASDAQ:NPCE) Short Interest UpdateApril 20, 2025 | marketbeat.comNeuroPace, Inc.: NeuroPace Provides Update on Tariff StatusApril 17, 2025 | finanznachrichten.deNeuroPace expects minimal impact from tariffsApril 15, 2025 | markets.businessinsider.comNeuroPace Provides Update on Tariff StatusApril 14, 2025 | globenewswire.comNeuroPace, Inc.: NeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual MeetingApril 8, 2025 | finanznachrichten.deNeuroPace announces data from long-term post-approval study of RNS SystemApril 8, 2025 | markets.businessinsider.comNeuroPace Announces Data From a Long-Term Post-Approval Study of the RNS System in Focal Epilepsy at the 2025 AAN Annual MeetingApril 8, 2025 | globenewswire.comQ1 Earnings Estimate for NeuroPace Issued By Leerink PartnrsApril 8, 2025 | marketbeat.comWells Fargo Remains a Buy on NeuroPace (NPCE)April 5, 2025 | markets.businessinsider.comNeuroPace (NPCE) Receives a Buy from Lake StreetApril 4, 2025 | markets.businessinsider.comNeuroPace to terminate distribution relationship for Seeg productsApril 3, 2025 | markets.businessinsider.comNeuroPace Announces Upcoming Oral Presentation of Data from the Long-Term Post-Approval Study of the RNS System at the 2025 AAN Annual MeetingApril 3, 2025 | globenewswire.comNeuroPace Announces Refocusing of Product PortfolioApril 2, 2025 | globenewswire.comNeuroPace to Present at the 24th Annual Needham Virtual Healthcare ConferenceMarch 26, 2025 | globenewswire.comNeuroPace at attractive entry point, remains best idea, says Cantor FitzgeraldMarch 19, 2025 | markets.businessinsider.comNeuroPace’s SWOT analysis: stock poised for growth amid expanding marketMarch 14, 2025 | investing.comNeuroPace, Inc. Reports Strong 2024 Growth Despite ChallengesMarch 5, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINFU, DCTH, CLPT, and NPCE Company DescriptionsClearPoint Neuro NASDAQ:CLPT$14.30 +1.02 (+7.64%) Closing price 03:59 PM EasternExtended Trading$14.25 -0.05 (-0.38%) As of 06:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.Delcath Systems NASDAQ:DCTH$14.35 +2.74 (+23.60%) Closing price 04:00 PM EasternExtended Trading$14.36 +0.01 (+0.03%) As of 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.InfuSystem NYSE:INFU$5.47 +0.72 (+15.16%) Closing price 04:00 PM EasternExtended Trading$5.47 0.00 (0.00%) As of 06:25 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.InfuSystem Holdings, Inc., through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states. The company also sells, rents, and leases new and pre-owned pole-mounted and ambulatory infusion pumps, and other durable medical equipment; sells treatment-related consumables; and provides biomedical recertification, maintenance, and repair services for oncology practices, as well as other healthcare site settings comprising hospitals, home care and home infusion providers, skilled nursing and acute care facilities, pain centers, and others. In addition, it offers local and field-based customer support, as well as operates pump service and repair centers. The company was incorporated in 2005 and is headquartered in Rochester Hills, Michigan.NeuroPace NASDAQ:NPCE$12.55 +0.43 (+3.55%) Closing price 04:00 PM EasternExtended Trading$12.53 -0.02 (-0.16%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
